Ascendis Pharma A/S (ASND) Shares Bought by RA Capital Management LLC
RA Capital Management LLC boosted its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 3.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,580,690 shares of the biotechnology company’s stock after purchasing an additional 170,700 shares during the period. Ascendis Pharma A/S comprises approximately 17.8% of RA Capital Management LLC’s investment portfolio, making the stock its biggest position. RA Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $154,920,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of ASND. Bank of Montreal Can grew its holdings in Ascendis Pharma A/S by 127.4% during the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock worth $126,000 after acquiring an additional 2,541 shares during the period. Victory Capital Management Inc. acquired a new stake in Ascendis Pharma A/S during the 1st quarter worth about $144,000. Bank of America Corp DE grew its holdings in Ascendis Pharma A/S by 23.6% during the 1st quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 1,020 shares during the period. Karp Capital Management Corp acquired a new stake in Ascendis Pharma A/S during the 1st quarter worth about $203,000. Finally, Deschutes Portfolio Strategy LLC acquired a new stake in Ascendis Pharma A/S during the 2nd quarter worth about $238,000. Institutional investors and hedge funds own 71.60% of the company’s stock.
A number of analysts have weighed in on ASND shares. Bank of America Corporation increased their price target on Ascendis Pharma A/S from $36.00 to $46.00 in a report on Thursday, September 28th. TheStreet downgraded Ascendis Pharma A/S from a “c-” rating to a “d” rating in a report on Thursday, June 15th. BidaskClub downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Leerink Swann reiterated a “hold” rating and set a $28.00 price target on shares of Ascendis Pharma A/S in a report on Friday, September 1st. Finally, Zacks Investment Research downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. Ascendis Pharma A/S has a consensus rating of “Hold” and a consensus price target of $36.95.
Ascendis Pharma A/S (ASND) traded up 2.934% during trading on Friday, hitting $35.615. 48,861 shares of the stock were exchanged. Ascendis Pharma A/S has a 52 week low of $17.15 and a 52 week high of $42.00.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Friday, August 18th. The biotechnology company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.24). Ascendis Pharma A/S had a negative return on equity of 67.76% and a negative net margin of 2,977.70%. The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $0.78 million. During the same period in the previous year, the firm earned ($0.53) EPS. The company’s revenue was down 61.4% on a year-over-year basis. On average, analysts anticipate that Ascendis Pharma A/S will post ($0.14) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Ascendis Pharma A/S (ASND) Shares Bought by RA Capital Management LLC” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/06/ascendis-pharma-as-asnd-shares-bought-by-ra-capital-management-llc.html.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Stock Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related stocks with our FREE daily email newsletter.